Viracta Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Reverse Merger | IPO

Total Raised


Market Cap


Stock Price


About Viracta Therapeutics

Viracta Therapeutics is a clinical-stage drug development company focused on advancing a proprietary viral activation therapy platform to address cancers associated with the Epstein-Barr Virus (EBV) and additional virus-associated diseases.

Viracta Therapeutics Headquarter Location

2533 S. Coast Hwy 101 Suite 210

Cardiff, California, 92007,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Viracta Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Viracta Therapeutics is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Viracta Therapeutics Patents

Viracta Therapeutics has filed 6 patents.

The 3 most popular patent topics include:

  • Experimental cancer drugs
  • Clusters of differentiation
  • Histone deacetylase inhibitors
patents chart

Application Date

Grant Date


Related Topics




Histone deacetylase inhibitors, Antineoplastic drugs, Transcription factors, Orphan drugs, Experimental cancer drugs


Application Date


Grant Date



Related Topics

Histone deacetylase inhibitors, Antineoplastic drugs, Transcription factors, Orphan drugs, Experimental cancer drugs



Latest Viracta Therapeutics News

16:05 EDT Viracta Therapeutics to Present at Upcoming May Investor Conferences

May 11, 2022

News provided by Share this article Share this article SAN DIEGO, May 11, 2022 /PRNewswire/ --  Viracta  Therapeutics, Inc. (Nasdaq: VIRX ), a precision oncology company targeting virus-associated malignancies, today announced that company management will present and participate in one-on-one meetings at the following investor conferences in May: RBC Capital Markets 2022 Global Healthcare Conference Presentation Date:         May 18, 2022 Presentation Time:         9:00 a.m. EDT Format:                           Fireside chat Presentation Date:         May 24, 2022 Presentation Time:         11:30 a.m. EDT Format:                           Fireside chat A live webcast of each presentation will be available on the Investors section of the Viracta website under "Events and Webcasts" at . The webcasts will be archived for 30 days. About Viracta Therapeutics, Inc. Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers. For additional information please visit . Investor Relations Contact:

Viracta Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Viracta Therapeutics Rank

You May Also Like


Palkion, Inc. is a private early stage company developing oral drugs to treat anemia based on the discovery and development of compounds that inhibit prolyl hydroxylase enzymes.

NeuroMolecular Pharmaceuticals

NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.

Bexion Pharmaceuticals

Bexion Pharmaceuticals is a company focused on the development of cures for cancer. Specifically, the company is interested in first entering the clinic with a glioma cancer indication, possibly simultaneously with a leukemia or pancreatic cancer indication.

Humanetics Corporation

Humanetics Corporation is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs with a focus on radiation modulators for oncology, medical imaging and medical countermeasure uses.


ThyroChek is the only available rapid test for elevated TSH approved by the FDA. It is a rapid, qualitative test for elevated TSH, thyroid stimulating hormone, a clinical indicator of hypothyroidism. Screening Devices Canada is producing products for the thyroid health market in the United States which is a market valued at $1.2B annually.

TRF Pharma

TRF Pharma is a hematology and oncology focused company, developing therapies to treat diseases of abberrant cell adhesion to endothelial (blood vessel) walls. Its programs in sickle cell disease and cancer metastasis are based on heparin derivatives and heparinoid drugs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.